In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.
The Australian startup emerges from stealth with former Solexa CEO Nick McCooke reprising that role at the firm.
China's National Natural Science Foundation is testing the use of artificial intelligence to find grant application reviewers, according to Nature News.
In Genome Biology this week: archaic gene flow into sub-Saharan African populations, a de novo transcriptome assembler, and more.
Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.
The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
Researchers uncovered deep-sea fish with additional rod pigment protein genes that may let them see color, according to the Los Angeles Times.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
US Food and Drug Administration has granted breakthrough device designation for Natera's circulating tumor DNA test, which is currently available for research.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.